RS57889B1 - Antitela sposobna za vezivanje faktora koagulacije xi i/ili njegovog aktiviranog oblika faktora xia i njihove primene - Google Patents

Antitela sposobna za vezivanje faktora koagulacije xi i/ili njegovog aktiviranog oblika faktora xia i njihove primene

Info

Publication number
RS57889B1
RS57889B1 RS20181219A RSP20181219A RS57889B1 RS 57889 B1 RS57889 B1 RS 57889B1 RS 20181219 A RS20181219 A RS 20181219A RS P20181219 A RSP20181219 A RS P20181219A RS 57889 B1 RS57889 B1 RS 57889B1
Authority
RS
Serbia
Prior art keywords
binding
antibodies capable
activated form
form factor
xia
Prior art date
Application number
RS20181219A
Other languages
English (en)
Inventor
Andreas Wilmen
Julia Strassburger
Frank Dittmer
Michael Strerath
Anja Buchmüller
Joanna Grudzinska-Goebel
Ricarda Finnern
Martina Schäfer
Christoph Gerdes
Hannah Jörissen
Asako Itakura
Leung Philberta Y
Erik Tucker
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of RS57889B1 publication Critical patent/RS57889B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
RS20181219A 2012-05-10 2013-05-08 Antitela sposobna za vezivanje faktora koagulacije xi i/ili njegovog aktiviranog oblika faktora xia i njihove primene RS57889B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP12167438 2012-05-10
EP12181697 2012-08-24
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30
PCT/EP2013/059618 WO2013167669A1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
EP13721746.9A EP2847228B1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Publications (1)

Publication Number Publication Date
RS57889B1 true RS57889B1 (sr) 2019-01-31

Family

ID=49550177

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181219A RS57889B1 (sr) 2012-05-10 2013-05-08 Antitela sposobna za vezivanje faktora koagulacije xi i/ili njegovog aktiviranog oblika faktora xia i njihove primene

Country Status (25)

Country Link
US (4) US9783614B2 (sr)
EP (2) EP2847228B1 (sr)
JP (2) JP6348900B2 (sr)
KR (1) KR102060376B1 (sr)
CN (1) CN104684932B (sr)
AR (1) AR091024A1 (sr)
AU (2) AU2013258043B2 (sr)
BR (1) BR112014027952B1 (sr)
CA (1) CA2872926C (sr)
DK (1) DK2847228T3 (sr)
ES (1) ES2698950T3 (sr)
HK (1) HK1207091A1 (sr)
HR (1) HRP20181680T1 (sr)
HU (1) HUE040580T2 (sr)
IL (1) IL235238B (sr)
LT (1) LT2847228T (sr)
MX (1) MX362454B (sr)
NZ (1) NZ701121A (sr)
PL (1) PL2847228T3 (sr)
RS (1) RS57889B1 (sr)
SG (2) SG10201609322QA (sr)
SI (1) SI2847228T1 (sr)
TW (2) TWI631140B (sr)
WO (1) WO2013167669A1 (sr)
ZA (1) ZA201407784B (sr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002298B1 (en) 2007-11-21 2019-08-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
PL2373691T3 (pl) 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
IN2014CN02805A (sr) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
AR088456A1 (es) 2011-10-14 2014-06-11 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9920034B2 (en) 2012-10-12 2018-03-20 Bristol-Myers Squibb Company Crystalline forms of a factor XIa inhibitor
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
US9777001B2 (en) 2014-01-31 2017-10-03 Bristol-Myers Squibb Company Macrocycles with aromatic P2′ groups as factor xia inhibitors
NO2760821T3 (sr) 2014-01-31 2018-03-10
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112017014308A2 (pt) 2015-01-02 2018-03-06 Dyax Corp anticorpos biespecíficos contra calicreína plasmática e fator xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
AU2017236063A1 (en) * 2016-03-23 2018-10-11 Prothix Bv Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102379580B1 (ko) 2016-06-14 2022-03-29 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
EP3535390A4 (en) * 2016-11-02 2020-11-25 Inc. Aronora COMBINATION OF THROMBIN E-WE ANALOGUE AND FIBRINOLYTIC
IL267538B1 (en) * 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
KR20190099256A (ko) * 2016-12-23 2019-08-26 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
PL3570882T3 (pl) * 2017-01-19 2022-02-07 Bayer Pharma Aktiengesellschaft Nowa stabilna formulacja dla przeciwciał fxia
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
AU2018372135A1 (en) * 2017-11-22 2020-05-28 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
JP7149721B2 (ja) 2018-03-26 2022-10-07 株式会社Pfu 情報処理装置、文字認識エンジン最適化方法及びプログラム
SG11202100046UA (en) * 2018-07-05 2021-02-25 Bayer Ag NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES
KR102382743B1 (ko) * 2018-08-01 2022-04-12 노보 노르디스크 에이/에스 개선된 응혈 촉진 항체
CN112514286A (zh) 2018-08-07 2021-03-16 日本电信电话株式会社 光传输系统和传输模式选择方法
MX2021001613A (es) * 2018-08-09 2021-04-28 Shanghai Benemae Pharmaceutical Corp Anticuerpos anti-factor xi.
WO2020061067A2 (en) * 2018-09-17 2020-03-26 Board Of Regents, The University Of Texas System Texas System Compositions and methods for treating bone injury
EP3873944A1 (en) 2018-10-31 2021-09-08 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
CA3125303A1 (en) * 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof
US20220162338A1 (en) 2019-04-16 2022-05-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TW202214701A (zh) * 2020-07-02 2022-04-16 大陸商北京拓界生物醫藥科技有限公司 抗ＦＸＩ／ＦＸＩａ抗體、其抗原結合片段及醫藥用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
ID22176A (id) 1996-10-14 1999-09-09 Bayer Ag Turunan pirazola tersubstitusi-heterosiklilmetil yang baru
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
JP5517619B2 (ja) 2006-08-18 2014-06-11 ノバルティス アーゲー Ｐｒｌｒ特異的抗体およびその使用
EP2152750A1 (en) 2007-04-23 2010-02-17 Schering Corporation Anti-mdl-1 antibodies
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
EP3002298B1 (en) 2007-11-21 2019-08-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2297207B1 (en) * 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
JP5501369B2 (ja) 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
PL2373691T3 (pl) * 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN103096718B (zh) 2010-05-27 2016-01-20 默沙东公司 可溶性鸟苷酸环化酶活化剂
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
MX359032B (es) 2011-09-01 2018-09-12 Hoffmann La Roche Inhibidores de pirrolopirazina cinasa.
SG11201400083VA (en) 2011-09-02 2014-06-27 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
SI2847228T1 (sl) 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe

Also Published As

Publication number Publication date
SI2847228T1 (sl) 2018-11-30
HUE040580T2 (hu) 2019-03-28
KR102060376B1 (ko) 2019-12-30
JP2018148920A (ja) 2018-09-27
AU2013258043A1 (en) 2014-11-13
PL2847228T3 (pl) 2019-03-29
KR20150008166A (ko) 2015-01-21
US20180112009A1 (en) 2018-04-26
ZA201407784B (en) 2019-01-30
WO2013167669A1 (en) 2013-11-14
SG10201609322QA (en) 2017-01-27
US20180051093A1 (en) 2018-02-22
CN104684932B (zh) 2019-03-12
SG11201406719UA (en) 2014-11-27
TW201400504A (zh) 2014-01-01
AU2013258043B2 (en) 2017-11-30
BR112014027952A2 (pt) 2019-07-09
HRP20181680T1 (hr) 2018-12-14
JP2015517305A (ja) 2015-06-22
IL235238B (en) 2019-08-29
LT2847228T (lt) 2018-11-12
CA2872926A1 (en) 2013-11-14
HK1207091A1 (en) 2016-01-22
CA2872926C (en) 2022-07-05
NZ701121A (en) 2017-06-30
DK2847228T3 (en) 2018-11-19
TWI644925B (zh) 2018-12-21
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
BR112014027952B1 (pt) 2022-06-21
MX2014013568A (es) 2014-12-08
ES2698950T3 (es) 2019-02-06
US11046783B2 (en) 2021-06-29
JP6348900B2 (ja) 2018-06-27
EP2847228A1 (en) 2015-03-18
US9783614B2 (en) 2017-10-10
TWI631140B (zh) 2018-08-01
AR091024A1 (es) 2014-12-30
AU2018200850A1 (en) 2018-02-22
TW201811834A (zh) 2018-04-01
EP2847228B1 (en) 2018-07-25
AU2018200850B2 (en) 2019-09-19
US20150099298A1 (en) 2015-04-09
AU2018200850C1 (en) 2020-03-12
EP3404045A1 (en) 2018-11-21
IL235238A0 (en) 2014-12-31
CN104684932A (zh) 2015-06-03
US10221247B2 (en) 2019-03-05
MX362454B (es) 2019-01-18

Similar Documents

Publication Publication Date Title
HRP20181680T1 (hr) Protutijela koja su sposobna vezati se na koagulacijski faktor xi i/ili njegov aktivirani oblik faktora xia i njegova upotreba
IL256716A (en) Antibodies against hla–b*27 and their uses
HK1211851A1 (en) Anti-dengue virus antibodies and uses thereof
HK1211302A1 (en) Asgpr antibodies and uses thereof asgpr
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
EP2872175A4 (en) RSPO3-BONDING SUBSTANCES AND USES THEREOF
HK1223385A1 (zh) 結合人類補體因子 的結合分子及其應用
PT2847228T (pt) Anticorpos com capacidade de se ligarem ao fator xi de coagulação e/ou à sua forma ativada fator xia e utilizações dos mesmos
GB201208372D0 (en) Antibodies and uses thereof